Thomas Galski, DO
Nuclear Cardiology · Moorestown, NJNPI 1811966187
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,676 and has fallen 57.4% since, to $714 in 2025.
Across 327 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impulse Dynamics (USA) Inc.$1K
- Boston Scientific$1K
- Amgen$889
- Novartis$379
- Pfizer$377
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$337
- plus $2K from 21 others
Across 18 payments — averaging $1710.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$17K
- Tosoh Bioscience, Inc.$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K
- Amgen$82
What the payments were for
- Consulting fees$5008%
- Food & beverage$5,84292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impulse Dynamics (USA) Inc. | 20 | $1,311 |
| Boston Scientific | 23 | $1,066 |
| Amgen | 60 | $889 |
| Novartis | 30 | $379 |
| Pfizer | 44 | $377 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $337 |
| Johnson & Johnson | 28 | $327 |
| Boehringer Ingelheim | 16 | $213 |
| Amarin Pharma, Inc. | 14 | $177 |
| AstraZeneca | 12 | $154 |
| Philips North America LLC | 8 | $132 |
| Abiomed | 1 | $128 |
| Heartflow, Inc. | 1 | $111 |
| Regeneron Healthcare Solutions, Inc. | 7 | $96 |
| Kestra Medical Technology Services, Inc. | 5 | $95 |
| Atricure, Inc. | 1 | $93 |
| E.r. Squibb & Sons, L.L.C. | 7 | $92 |
| Esperion Therapeutics, Inc. | 5 | $61 |
| Sanofi-aventis U.S. LLC | 5 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Irhythm Technologies, Inc. | 2 | $39 |
| Merck | 2 | $33 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Avinger Inc. | 1 | $24 |
| Gilead | 2 | $23 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER SMART SYSTEM$680
- WATCHMAN FLX$149
- EMBLEM$139
- WATCHMAN Access System$129
- Watchman$118
- FFRct$111
How this compares
$6,342 in reported general payments places this provider in the 60th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 814 | $864,324 |
| Repatha SureclickEvolocumab | 212 | $247,596 |
| EntrestoSacubitril/Valsartan | 154 | $174,357 |
| XareltoRivaroxaban | 138 | $172,502 |
| Praluent PenAlirocumab | 64 | $73,179 |
| BrilintaTicagrelor | 39 | $41,355 |
| JardianceEmpagliflozin | 33 | $40,030 |
| FarxigaDapagliflozin Propanediol | 25 | $23,865 |
| Rosuvastatin Calcium | 827 | $12,634 |
| Metoprolol Succinate | 918 | $12,299 |
| LivaloPitavastatin Calcium | 11 | $9,955 |
| Icosapent Ethyl | 25 | $9,452 |
| Carvedilol ErCarvedilol Phosphate | 16 | $8,938 |
| Ezetimibe | 387 | $7,668 |
| Atorvastatin Calcium | 645 | $7,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $377 | $864,324814 claims |
| NovartisEntresto | $379 | $174,357154 claims |
| Johnson & JohnsonXarelto | $327 | $172,502138 claims |
| AstraZenecaBrilinta, Farxiga | $154 | $65,22064 claims |
| Boehringer IngelheimJardiance | $213 | $40,03033 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $47 | $9,95511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Moorestown
- Ralph RussoMoorestown$11K
- Anthony SauerweinMoorestown$10K
- Samuel VentrellaMoorestown$7K
- Jay SussmanMoorestown$3K
- Antonio ValoneMoorestown$3K
- Pamela FazioMoorestown$2K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.